Literature DB >> 24619556

E2F1 is a novel fibrogenic gene that regulates cholestatic liver fibrosis through the Egr-1/SHP/EID1 network.

Yuxia Zhang1, Ningyi Xu, Jun Xu, Bo Kong, Bryan Copple, Grace L Guo, Li Wang.   

Abstract

UNLABELLED: E2F transcription factor 1 (E2F1) is an important regulator of metabolic diseases; however, its role in liver function remains elusive. This study unraveled a regulatory cascade involving E2F1, early growth response-1 (Egr-1), nuclear receptor small heterodimer partner (SHP, NR0B2), and EIA-like inhibitor of differentiation 1 (EID1) in cholestatic liver fibrosis. Liver E2F1 messenger RNA (mRNA) and protein expression was strongly up-regulated in human nonalcoholic steatohepatitis (NASH) and alcohol cirrhosis; the latter was inversely correlated with diminished SHP expression. E2F1 was also highly induced by 3,5-diethoxycarbonyl-1, 4-dihydrocollidine (DDC) feeding and bile-duct ligation (BDL) in mice. E2F1-/- mice exhibited reduced biliary fibrosis by DDC as determined by Masson Trichrome and Picro Sirius red staining, and decreased serum bile acid (BA), BA pool size, and fecal BA excretion. In addition, cholestatic liver fibrosis induced by BDL, as determined by immunohistochemistry analysis of a1 collagen expression, was increased in SHP-/- mice but attenuated in hepatocyte SHP-overexpressed transgenic (STG) mice. Egr-1 exhibited marked induction in livers of SHP-/- mice compared to the wild-type mice in both sham and BDL groups, and reduction in STG livers. Egr-1 promoter was activated by E2F1, and the activation was abrogated by expression of SHP and its co-repressor EID1 in hepatoma cells Huh7, Hepa1, and stellate cells LX2. Chromatin immunoprecipitation assays further confirmed the association of E2F1, SHP, and EID1 proteins with the Egr-1 promoter, and their direct protein interactions were determined by glutathione S-transferase pull-down assays. Interestingly, E2F1 activated Egr-1 expression in a biphasic fashion as described in both human and mouse hepatocytes.
CONCLUSION: E2F1 is a fibrogenic gene and could serve as a potential new diagnostic marker for nonalcoholic and alcoholic liver fibrosis/cirrhosis.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24619556      PMCID: PMC4146672          DOI: 10.1002/hep.27121

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  32 in total

1.  Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis.

Authors:  Tatiana Kisseleva; Hiroshi Uchinami; Nikki Feirt; Oscar Quintana-Bustamante; Jose Carlos Segovia; Robert F Schwabe; David A Brenner
Journal:  J Hepatol       Date:  2006-06-09       Impact factor: 25.083

2.  Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation.

Authors:  Yuxia Zhang; Ping Xu; Kyungtae Park; Yunhee Choi; David D Moore; Li Wang
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

Review 3.  Mechanisms of hepatic fibrogenesis.

Authors:  Scott L Friedman
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

4.  Cell cycle regulators in the control of metabolism.

Authors:  Emilie Blanchet; Jean-Sébastien Annicotte; Lluis Fajas
Journal:  Cell Cycle       Date:  2009-12-17       Impact factor: 4.534

5.  Early growth response factor-1 is critical for cholestatic liver injury.

Authors:  Nam Deuk Kim; Jeon-Ok Moon; Angela L Slitt; Bryan L Copple
Journal:  Toxicol Sci       Date:  2006-01-19       Impact factor: 4.849

6.  The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis.

Authors:  Stefano Fiorucci; Elisabetta Antonelli; Giovanni Rizzo; Barbara Renga; Andrea Mencarelli; Luisa Riccardi; Stefano Orlandi; Roberto Pellicciari; Antonio Morelli
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition.

Authors:  Michael Zeisberg; Changqing Yang; Margot Martino; Michael B Duncan; Florian Rieder; Harikrishna Tanjore; Raghu Kalluri
Journal:  J Biol Chem       Date:  2007-06-11       Impact factor: 5.157

8.  Genome-wide mapping of RELA(p65) binding identifies E2F1 as a transcriptional activator recruited by NF-kappaB upon TLR4 activation.

Authors:  Ching-Aeng Lim; Fei Yao; Joyce Jing-Yi Wong; Joshy George; Han Xu; Kuo Ping Chiu; Wing-Kin Sung; Leonard Lipovich; Vinsensius B Vega; Joanne Chen; Atif Shahab; Xiao Dong Zhao; Martin Hibberd; Chia-Lin Wei; Bing Lim; Huck-Hui Ng; Yijun Ruan; Keh-Chuang Chin
Journal:  Mol Cell       Date:  2007-08-17       Impact factor: 17.970

9.  Loss of orphan receptor small heterodimer partner sensitizes mice to liver injury from obstructive cholestasis.

Authors:  Young Joo Park; Mohammed Qatanani; Steven S Chua; Jennifer L LaRey; Stacy A Johnson; Mitsuhiro Watanabe; David D Moore; Yoon Kwang Lee
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

10.  A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis.

Authors:  Peter Fickert; Ulrike Stöger; Andrea Fuchsbichler; Tarek Moustafa; Hanns-Ulrich Marschall; Andreas H Weiglein; Oleksiy Tsybrovskyy; Hartmut Jaeschke; Kurt Zatloukal; Helmut Denk; Michael Trauner
Journal:  Am J Pathol       Date:  2007-06-28       Impact factor: 4.307

View more
  59 in total

1.  Knockout of the Tachykinin Receptor 1 in the Mdr2-/- (Abcb4-/-) Mouse Model of Primary Sclerosing Cholangitis Reduces Biliary Damage and Liver Fibrosis.

Authors:  Ludovica Ceci; Heather Francis; Tianhao Zhou; Thao Giang; Zhihong Yang; Fanyin Meng; Nan Wu; Lindsey Kennedy; Konstantina Kyritsi; Vik Meadows; Chaodong Wu; Suthat Liangpunsakul; Antonio Franchitto; Amelia Sybenga; Burcin Ekser; Romina Mancinelli; Paolo Onori; Eugenio Gaudio; Shannon Glaser; Gianfranco Alpini
Journal:  Am J Pathol       Date:  2020-07-23       Impact factor: 4.307

2.  H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of epithelial cell adhesion molecule.

Authors:  Yongfeng Song; Chune Liu; Xia Liu; Jocelyn Trottier; Michele Beaudoin; Li Zhang; Chad Pope; Guangyong Peng; Olivier Barbier; Xiaobo Zhong; Linheng Li; Li Wang
Journal:  Hepatology       Date:  2017-08-26       Impact factor: 17.425

3.  Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase-A/5-Hydroxytryptamine/5-Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis.

Authors:  Konstantina Kyritsi; Lixian Chen; April O'Brien; Heather Francis; Travis W Hein; Julie Venter; Nan Wu; Ludovica Ceci; Tianhao Zhou; David Zawieja; Anatoliy A Gashev; Fanyin Meng; Pietro Invernizzi; Luca Fabris; Chaodong Wu; Nicholas J Skill; Romil Saxena; Suthat Liangpunsakul; Gianfranco Alpini; Shannon S Glaser
Journal:  Hepatology       Date:  2019-10-18       Impact factor: 17.425

4.  Long noncoding RNA H19 interacts with polypyrimidine tract-binding protein 1 to reprogram hepatic lipid homeostasis.

Authors:  Chune Liu; Zhihong Yang; Jianguo Wu; Li Zhang; Sangmin Lee; Dong-Ju Shin; Melanie Tran; Li Wang
Journal:  Hepatology       Date:  2018-03-25       Impact factor: 17.425

5.  A Novel Small Molecule Activator of Nuclear Receptor SHP Inhibits HCC Cell Migration via Suppressing Ccl2.

Authors:  Zhihong Yang; Angela N Koehler; Li Wang
Journal:  Mol Cancer Ther       Date:  2016-08-02       Impact factor: 6.261

6.  Dynamic transcription factor activity networks in response to independently altered mechanical and adhesive microenvironmental cues.

Authors:  Beatriz Peñalver Bernabé; Seungjin Shin; Peter D Rios; Linda J Broadbelt; Lonnie D Shea; Stephanie K Seidlits
Journal:  Integr Biol (Camb)       Date:  2016-07-29       Impact factor: 2.192

7.  E2F1 inhibits circulating cholesterol clearance by regulating Pcsk9 expression in the liver.

Authors:  Qiuwen Lai; Albert Giralt; Cédric Le May; Lianjun Zhang; Bertrand Cariou; Pierre-Damien Denechaud; Lluis Fajas
Journal:  JCI Insight       Date:  2017-05-18

8.  REV-ERBα Activates C/EBP Homologous Protein to Control Small Heterodimer Partner-Mediated Oscillation of Alcoholic Fatty Liver.

Authors:  Zhihong Yang; Hiroyuki Tsuchiya; Yuxia Zhang; Sangmin Lee; Chune Liu; Yi Huang; Gymar M Vargas; Li Wang
Journal:  Am J Pathol       Date:  2016-09-21       Impact factor: 4.307

9.  E2F1 mediates sustained lipogenesis and contributes to hepatic steatosis.

Authors:  Pierre-Damien Denechaud; Isabel C Lopez-Mejia; Albert Giralt; Qiuwen Lai; Emilie Blanchet; Brigitte Delacuisine; Brandon N Nicolay; Nicholas J Dyson; Caroline Bonner; François Pattou; Jean-Sébastien Annicotte; Lluis Fajas
Journal:  J Clin Invest       Date:  2015-11-30       Impact factor: 14.808

Review 10.  Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?

Authors:  Swetha Rudraiah; Xi Zhang; Li Wang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.